TW201821062A - 溴結構域抑制劑 - Google Patents

溴結構域抑制劑 Download PDF

Info

Publication number
TW201821062A
TW201821062A TW106136093A TW106136093A TW201821062A TW 201821062 A TW201821062 A TW 201821062A TW 106136093 A TW106136093 A TW 106136093A TW 106136093 A TW106136093 A TW 106136093A TW 201821062 A TW201821062 A TW 201821062A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
cyclopropylmethoxy
polymer
compound
methylisoquinolin
Prior art date
Application number
TW106136093A
Other languages
English (en)
Chinese (zh)
Inventor
胡安曼努爾 貝坦科特
傑佛瑞艾倫 史塔福德
萊恩 史丹斯菲爾德
詹姆士馬文 維爾
Original Assignee
美商塞爾基因定量細胞研究公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商塞爾基因定量細胞研究公司 filed Critical 美商塞爾基因定量細胞研究公司
Publication of TW201821062A publication Critical patent/TW201821062A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW106136093A 2016-10-20 2017-10-20 溴結構域抑制劑 TW201821062A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662410756P 2016-10-20 2016-10-20
US62/410,756 2016-10-20

Publications (1)

Publication Number Publication Date
TW201821062A true TW201821062A (zh) 2018-06-16

Family

ID=62019669

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106136093A TW201821062A (zh) 2016-10-20 2017-10-20 溴結構域抑制劑

Country Status (7)

Country Link
EP (1) EP3528810A4 (enExample)
JP (3) JP7129973B2 (enExample)
CN (1) CN110099685A (enExample)
AR (1) AR109859A1 (enExample)
AU (1) AU2017345468B2 (enExample)
TW (1) TW201821062A (enExample)
WO (1) WO2018075796A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
AU2019309693B2 (en) * 2018-07-23 2023-03-16 Celgene Quanticel Research, Inc. Process for the preparation of bromodomain inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN105899212A (zh) * 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
US9884806B2 (en) * 2013-08-30 2018-02-06 Icahn School Of Medicine At Mount Sinai Cyclic vinylogous amides as bromodomain inhibitors
EP3290407B1 (en) * 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
JP2016538310A (ja) * 2013-11-27 2016-12-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法
TW201642860A (zh) * 2015-04-22 2016-12-16 塞爾基因定量細胞研究公司 布羅莫結構域抑制劑
CN105732624B (zh) * 2016-01-28 2019-08-02 中国药科大学 吡咯[4,3,2-de]喹啉-2(1H)-酮类BRD4蛋白抑制剂的制备方法及其用途

Also Published As

Publication number Publication date
EP3528810A4 (en) 2020-06-17
AU2017345468B2 (en) 2022-06-02
WO2018075796A1 (en) 2018-04-26
JP2024056905A (ja) 2024-04-23
EP3528810A1 (en) 2019-08-28
AU2017345468A1 (en) 2019-06-06
CN110099685A (zh) 2019-08-06
AR109859A1 (es) 2019-01-30
JP7129973B2 (ja) 2022-09-02
JP2022095897A (ja) 2022-06-28
JP2019535671A (ja) 2019-12-12

Similar Documents

Publication Publication Date Title
CA2983446C (en) Bromodomain inhibitor
TWI828817B (zh) 用於治療或預防痛風或高尿酸血症之化合物晶型
JP7528080B2 (ja) 痛風または高尿酸血症を処置または予防するための方法
JP2024056905A (ja) ブロモドメイン阻害剤
TW202108561A (zh) 用於治療痛風或高尿酸血症之化合物
US20230301983A1 (en) Bromodomain inhibitor
JP2020532522A (ja) 感覚有毛細胞死を予防または処置するための化合物の結晶形態
CA3121913C (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
WO2026085383A1 (en) Crystalline forms of an nlrp3 modulator
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia